Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder | NCT00290914 | Trialant
CompletedInterventionalPhase 2Updated May 9, 2012
Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder
ClinicalTrials.gov ID
NCT00290914
Lead Sponsor
Pharmacology Research InstituteOTHER
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Last Update Posted
May 9, 2012Estimated
Brief Summary
The purpose is to evaluate the safety and usefulness of the investigational drug, vilazodone in depression.
Major Depressive Disorder
Vilazodone
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female patients 18-65 years of age, inclusive.